Welcome to our dedicated page for Cvs Health news (Ticker: CVS), a resource for investors and traders seeking the latest updates and insights on Cvs Health stock.
CVS Health Corporation operates an integrated health care model that combines retail pharmacy, pharmacy benefit management, health insurance, medical clinics, specialty and mail pharmacy support, and related consumer health services. Recurring company news includes quarterly results and guidance, segment performance across Health Services, Health Care Benefits, and Pharmacy & Consumer Wellness, and capital returns through common-stock dividends.
Updates also cover CVS Caremark formulary decisions, biosimilar adoption, Aetna prior authorization and plan-administration initiatives, community health investments by the CVS Health Foundation, and developments involving Omnicare, the company's long-term care pharmacy subsidiary.
CVS (NYSE: CVS) reported Q1 2026 total revenue of $100.4 billion, up 6.2% year-over-year, GAAP diluted EPS of $2.30 and Adjusted EPS of $2.57. The company raised full-year 2026 guidance to GAAP EPS $6.24–$6.44, Adjusted EPS $7.30–$7.50, and cash flow from operations to at least $9.5 billion.
Segment highlights include Health Care Benefits margin improvement (MBR 84.6%), Health Services revenue growth to $48.2 billion, and Pharmacy prescriptions up to 451.2 million (30-day equivalent).
CVS (NYSE: CVS) will update its most common commercial template formularies effective July 1, 2026 to prefer FDA‑approved biosimilars, including interchangeable options, to expand access and lower costs. Key moves include transitioning Stelara (ustekinumab) to biosimilars Pyzchiva and Yesintek and broader specialty category coverage.
The changes aim to reduce member out‑of‑pocket costs (most members may pay $0) and deliver client savings while providing communications and clinical support for transitions.
Aetna (NYSE: CVS) announced progress simplifying prior authorization to speed access to care. Key metrics: 88% of prior authorization volume standardized, 95%+ of eligible requests approved within 24 hours, 83% processed in real time, and over 1 million provider calls eliminated.
The company also launched bundled, condition-specific prior authorization programs and integrated medical and pharmacy decisions into single reviews to streamline approvals for patients and providers.
Aetna (NYSE: CVS) released results from the inaugural Aetna Provider Survey (Q1 2026), polling 827 U.S. providers (±3% margin). Key findings: 60% expect health care to become less burdensome in five years, trust score >50%, 65% accept prior authorization roles, and >95% of eligible PAs approved within 24 hours.
Aetna set a target of >80% real-time electronic prior authorizations by year-end 2026 and automated over 1 million provider calls about prior authorization in 2025.
CVS Health (NYSE: CVS) will hold its first quarter 2026 earnings conference call on Wednesday, May 6, 2026 at 8:00 a.m. ET. An audio webcast will stream on the company's investor relations site and will be archived there for one year.
Omnicare (NYSE: CVS) entered an asset purchase agreement with GenieRx, which will act as the stalking horse bidder in Omnicare's court‑supervised sale process.
The bid establishes a sale floor; competing bids are due April 30, 2026, an auction is expected May 5, 2026, and a court hearing to approve the winning bid will follow. Omnicare says it will continue serving skilled nursing and assisted living customers during the process.
CVS (NYSE:CVS) opened its first pharmacy-only location in Chicago on March 30, 2026, part of a plan to open nearly 20 pharmacy-only sites this year and more than 40 new CVS Pharmacy locations including traditional and Target stores. Sites average ~3,000 sq ft and focus on prescriptions, immunizations and pharmacist counseling.
The format complements existing store types and targets communities needing increased access to in-person pharmacy care.
CVS Health (NYSE: CVS) declared a quarterly dividend of $0.665 per share. The board approved the payment, which is payable on May 4, 2026 to shareholders of record on April 23, 2026.
This announcement details the dividend amount, record date, and payment date for common stockholders.
CVS Health (NYSE:CVS) is investing $2.24 million to launch a Health Zone in Charlotte's Historic West End through the Westside Wellness Collab led by LISC Charlotte.
The three‑year effort funds mobile clinics, fresh food distribution, care coordination and partner capacity building to improve chronic‑condition support and food access.
CVS Health (NYSE:CVS) announced a $2.24 million investment in Health Impact Ohio to launch a Health Zone in Columbus on March 10, 2026. The funding expands Community Health Worker capacity, maternal and behavioral health services, training and data systems to reduce avoidable emergency care and improve care coordination.
The investment builds on CVS's broader Ohio footprint, including workforce centers, affordable housing investments (~$80 million) and reported FY2024 economic contributions.